1310340-58-9 Usage
Description
VBY-825 is a novel, reversible cathepsin inhibitor with high potency against cathepsins B, L, S, and V. It is a new and effective anti-tumor drug that has the potential to be used in various applications across different industries.
Uses
Used in Pharmaceutical Industry:
VBY-825 is used as an anti-tumor drug for its high potency against cathepsins, which are enzymes involved in the degradation of proteins and peptides. By inhibiting these enzymes, VBY-825 can help in the treatment of various types of cancer.
Used in Cancer Research:
VBY-825 is used as a research tool for studying the role of cathepsins in cancer progression and metastasis. Its reversible inhibition of cathepsins can provide valuable insights into the underlying mechanisms of tumor growth and help in the development of targeted cancer therapies.
Used in Drug Development:
VBY-825 is used as a lead compound in the development of new drugs targeting cathepsins for cancer treatment. Its high potency and reversibility make it an attractive candidate for further optimization and improvement to enhance its therapeutic potential.
Used in Drug Delivery Systems:
VBY-825 can be used in the development of novel drug delivery systems to improve its bioavailability, delivery, and therapeutic outcomes. By employing various organic and metallic nanoparticles as carriers, the limitations of VBY-825 can be overcome, leading to enhanced efficacy against cancer cells.
Check Digit Verification of cas no
The CAS Registry Mumber 1310340-58-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,0,3,4 and 0 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1310340-58:
(9*1)+(8*3)+(7*1)+(6*0)+(5*3)+(4*4)+(3*0)+(2*5)+(1*8)=89
89 % 10 = 9
So 1310340-58-9 is a valid CAS Registry Number.
1310340-58-9Relevant articles and documents
CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN
-
, (2012/11/13)
The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.
